China Resources Sanjiu Medical & Pharmaceutical Co (000999) Q2 2025 earnings summary

Executive summary

• Revenue for H1 2025 reached ¥14.81 billion, up 4.99% year-over-year, while net profit attributable to shareholders was ¥1.82 billion, down 24.31% year-over-year due to a high base and market adjustments.

• Cash flow from operating activities increased 21.03% year-over-year to ¥2.86 billion.

• Completed acquisition of a 28% stake in Tasly, making it a controlling subsidiary and expanding the business portfolio.

• Proposed interim dividend of ¥4.5 per 10 shares, representing 41.39% of H1 net profit.

Financial highlights

• Operating income: ¥14.81 billion, up 4.99% year-over-year.

• Net profit attributable to shareholders: ¥1.82 billion, down 24.31% year-over-year.

• Basic and diluted EPS: ¥1.09, down from ¥1.44 year-over-year.

• Gross margin for self-medication (CHC) segment: 60.50%; prescription drugs: 58.47%.

• Total assets at period end: ¥57.26 billion, up 42.86% from year-end 2024.

Outlook and guidance

• Management expects full-year 2025 revenue growth to outpace the industry average, targeting double-digit growth.

• Focus on expanding R&D pipeline, accelerating innovation, and leveraging synergies from recent acquisitions.

• Continued emphasis on high-quality growth, brand leadership, and digital transformation.